Riskpilot← Back to searchSign inGet full accessMoonpharma AB
ABActiveOrg 5568119019Tellusvägen 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20100 employees
Revenue 2025
—
EBITDA margin
—
+96% vs 2024
Equity ratio
96.8%
Financial strength
Net profit 2025
SEK -2K
+96% vs 2024
| Revenue | — | — |
| EBITDA | SEK -2K | +96% |
| Net profit | SEK -2K | +96% |
| Total assets | SEK 1,9M | +0% |
| Equity | SEK 1,9M | +0% |
| Employees | 0 | — |
Legal name
Moonpharma AB
Org number
5568119019
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 juni 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Föremålet för bolagets verksamhet skall vara agenturverksamhet med läkemedel, handel med OTC-läkemedel, mineraler, metaller samt handelsvaror inom läkemedel, konsultverksamhet inom läkemedelsindustrin, även handel med värdepapper, fast och lös egendom samt därmed förenlig verksamhet.
Address
Tellusvägen 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −172 | −35 | −41 | −56 | −2 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −172 | −35 | −41 | −56 | −2 |
| Net financials | — | — | 1 230 | −0 | −0 |
| Profit before tax | −172 | −35 | 1 189 | −56 | −2 |
| Tax | −0 | — | — | — | — |
| Net profit | −172 | −35 | 1 189 | −56 | −2 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 896 | 1 917 | 1 924 | 1 924 | 1 923 |
| Equity | 766 | 731 | 1 920 | 1 865 | 1 862 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 1 130 | 1 185 | 4 | 59 | 61 |
| Total debt | 1 130 | 1 185 | 4 | 59 | 61 |
EBITDA margin
-236000.0%
This company
15.8%
Market median
-1493771% vs market
20212025
Equity ratio
96.8%
This company
38.2%
Market median
+153% vs market
20212025
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20212025
Net profit margin
-236200.0%
This company
8.1%
Market median
-2916149% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Moonpharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Louise Jeanette Marianne Falkenberg | Deputy Board Member | 0 companies |
| Mats Ohlsson | Board of Directors | 0 companies |
| Pontus Ragnar Gustav Olsson | Deputy Board Member | 0 companies |